Cardiol Therapeutics Inc. (NASDAQ:CRDL – Free Report) – Roth Capital issued their Q2 2024 earnings estimates for shares of Cardiol Therapeutics in a report issued on Wednesday, June 26th. Roth Capital analyst J. Wittes expects that the company will post earnings per share of ($0.09) for the quarter. Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.34) per share. Roth Capital also issued estimates for Cardiol Therapeutics’ Q3 2024 earnings at ($0.09) EPS, Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.35) EPS, Q1 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.39) EPS.
Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) last released its earnings results on Tuesday, May 14th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.04).
Get Our Latest Stock Report on CRDL
Cardiol Therapeutics Stock Performance
Shares of CRDL opened at $2.02 on Friday. The firm’s 50 day moving average is $2.21 and its 200-day moving average is $1.65. The stock has a market capitalization of $139.38 million, a P/E ratio of -5.77 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.81 and a quick ratio of 2.81. Cardiol Therapeutics has a 12-month low of $0.66 and a 12-month high of $3.12.
Institutional Investors Weigh In On Cardiol Therapeutics
A hedge fund recently raised its stake in Cardiol Therapeutics stock. Laird Norton Trust Company LLC grew its position in Cardiol Therapeutics Inc. (NASDAQ:CRDL – Free Report) by 63.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 100,000 shares of the company’s stock after purchasing an additional 38,673 shares during the quarter. Laird Norton Trust Company LLC owned approximately 0.15% of Cardiol Therapeutics worth $90,000 as of its most recent SEC filing. Institutional investors and hedge funds own 12.49% of the company’s stock.
Cardiol Therapeutics Company Profile
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Featured Stories
- Five stocks we like better than Cardiol Therapeutics
- The Significance of Brokerage Rankings in Stock Selection
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- How to Calculate Options Profits
- MarketBeat Week in Review – 6/24 – 6/28
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.